guest ::
| Home > Publications database > Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. > print |
| Home > Publications database > Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. > print |
| 001 | 284981 | ||
| 005 | 20240229155059.0 | ||
| 024 | 7 | _ | |a 10.1038/s41467-023-42400-5 |2 doi |
| 024 | 7 | _ | |a pmid:37875494 |2 pmid |
| 024 | 7 | _ | |a altmetric:155704764 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-02165 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 500 |
| 100 | 1 | _ | |a Pouyiourou, Maria |0 P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. |
| 260 | _ | _ | |a [London] |c 2023 |b Nature Publishing Group UK |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1698305078_31145 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:A360#LA:A360# |
| 520 | _ | _ | |a Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Phase II trial (EudraCT 2018-004562-33; NCT04131621), patients relapsed or refractory after platinum-based chemotherapy received nivolumab and ipilimumab following TMBhigh vs. TMBlow stratification. Progression-free survival (PFS) represented the primary endpoint; overall survival (OS), response rates, duration of clinical benefit and safety were the secondary endpoints. The trial was prematurely terminated in March 2021 before reaching the preplanned sample size (n = 194). Among 31 evaluable patients, 16% had a high TMB ( > 12 mutations/Mb). Overall response rate was 16% (95% CI 6-34%), with 7.7% (95% CI 1-25%) vs. 60% (95% CI 15-95%) in TMBlow and TMBhigh, respectively. Although the primary endpoint was not met, high TMB was associated with better median PFS (18.3 vs. 2.4 months) and OS (18.3 vs. 3.6 months). Severe immune-related adverse events were reported in 29% of cases. Assessing on-treatment dynamics of circulating tumor DNA using combined targeted hotspot mutation and shallow whole genome sequencing as part of a predefined exploratory analysis identified patients benefiting from immunotherapy irrespective of initial radiologic response. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Kraft, Bianca |0 P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8 |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Wohlfromm, Timothy |0 P:(DE-He78)de9da69e07eba6d0ca82a4f087a64a28 |b 2 |u dkfz |
| 700 | 1 | _ | |a Stahl, Michael |b 3 |
| 700 | 1 | _ | |a Kubuschok, Boris |0 0000-0001-5000-2328 |b 4 |
| 700 | 1 | _ | |a Löffler, Harald |b 5 |
| 700 | 1 | _ | |a Hacker, Ulrich T |b 6 |
| 700 | 1 | _ | |a Hübner, Gerdt |b 7 |
| 700 | 1 | _ | |a Weiss, Lena |b 8 |
| 700 | 1 | _ | |a Bitzer, Michael |0 0000-0002-4463-8263 |b 9 |
| 700 | 1 | _ | |a Ernst, Thomas |0 0000-0003-2147-489X |b 10 |
| 700 | 1 | _ | |a Schütt, Philipp |b 11 |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 12 |u dkfz |
| 700 | 1 | _ | |a Delorme, Stefan |0 P:(DE-He78)3e76653311420a51a5faeb80363bd73e |b 13 |u dkfz |
| 700 | 1 | _ | |a Kirchner, Martina |b 14 |
| 700 | 1 | _ | |a Kazdal, Daniel |b 15 |
| 700 | 1 | _ | |a Ball, Markus |0 0000-0002-2312-8360 |b 16 |
| 700 | 1 | _ | |a Kluck, Klaus |b 17 |
| 700 | 1 | _ | |a Stenzinger, Albrecht |0 0000-0003-1001-103X |b 18 |
| 700 | 1 | _ | |a Bochtler, Tilmann |0 P:(DE-He78)c741dc7f974390ad4310349f29aac40b |b 19 |u dkfz |
| 700 | 1 | _ | |a Krämer, Alwin |0 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0 |b 20 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/s41467-023-42400-5 |g Vol. 14, no. 1, p. 6761 |0 PERI:(DE-600)2553671-0 |n 1 |p 6761 |t Nature Communications |v 14 |y 2023 |x 2041-1723 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:284981 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)de9da69e07eba6d0ca82a4f087a64a28 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)3e76653311420a51a5faeb80363bd73e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)c741dc7f974390ad4310349f29aac40b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT COMMUN : 2022 |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T09:09:09Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T09:09:09Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2023-05-02T09:09:09Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2023-05-02T09:09:09Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1060 |2 StatID |b Current Contents - Agriculture, Biology and Environmental Sciences |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2023-08-29 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NAT COMMUN : 2022 |d 2023-08-29 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-29 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-29 |
| 920 | 2 | _ | |0 I:(DE-He78)A360-20160331 |k A360 |l KKE Mol. Hämatologie/Onkologie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)A360-20160331 |k A360 |l KKE Mol. Hämatologie/Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A360-20160331 |k A360 |l KKE Mol. Hämatologie/Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l E010 Radiologie |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A360-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E010-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|